Stem Cell Therapy for Type 1 Diabetes: Moving from Lab to Patient Care

Type 1 diabetes occurs when the immune system attacks and destroys the insulin-producing beta cells in the pancreas. Without these cells, the body cannot regulate blood sugar properly. Currently, people with Type 1 diabetes manage their condition through insulin injections or pumps and careful monitoring, but these treatments do not restore the body's natural ability to make insulin.

One potential solution is to replace the damaged beta cells with new ones grown in the laboratory. However, creating high-quality insulin-producing cells from stem cells has been difficult, with earlier methods often producing inconsistent results. Researchers are now working to solve this problem.

Scientists at Karolinska Institutet and KTH Royal Institute of Technology have developed an improved method for generating insulin-producing cells from human stem cells. This refined process produces more mature and purer cells than previous techniques, according to research published in Stem Cell Reports.

In laboratory tests, these newly created cells successfully secreted insulin and responded appropriately to glucose, mimicking the behavior of healthy beta cells. When researchers transplanted these cells into diabetic mice—placing them in the eye's anterior chamber—the animals gradually regained the ability to regulate their blood sugar on their own. These results demonstrate proof of concept, showing that the approach can work in living organisms.

A stem cell therapy called zimislecel has entered human testing. In a phase 1-2 clinical trial published in The New England Journal of Medicine, 14 participants with Type 1 diabetes received an infusion of zimislecel cells into the liver (portal vein), along with immunosuppressive medications to prevent rejection. Researchers tracked whether the transplanted cells survived, functioned, and reduced the need for insulin.

Initial findings suggest that the transplanted cells can engraft and produce insulin, though the research is still in its early stages. A complete picture of safety and long-term effectiveness will require more time and larger studies. Participants have been followed for at least 12 months so far.

Currently, human islet cell transplants from deceased donors are an established treatment for insulin-requiring Type 1 diabetes. However, demand far exceeds the supply of available donor organs. Stem cell-derived islet cells offer a potential solution: they could be produced in unlimited quantities from a laboratory, rather than relying on a limited supply of donor pancreases.

The scientific and clinical progress over the last decade has been substantial, and researchers are working to overcome the regulatory and technical hurdles needed to bring this therapy into wider use. The challenge now is ensuring that stem cell-derived cells are safe, effective, and economically viable for patients.

Stem cell therapy for Type 1 diabetes remains experimental. It is not yet approved as a standard treatment and is available only through clinical trials. People interested in participating in research should speak with their healthcare team about ongoing studies in their area.

While these early results are promising, it is important to continue managing Type 1 diabetes with current proven methods—insulin therapy, blood sugar monitoring, and regular medical care. As research progresses, patients will have clearer information about whether stem cell therapy might become a treatment option in the future.

Origin: news.ki.se (News report). Evidence: News report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.